Companies see a commercial opportunity in creating new ways to administer drugs to patients – in space.

A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk ...

In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational ...

Daraxonrasib doubles survival — a RAS‑targeting drug development breakthrough.

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions Pfizer to leverage Chi ...

Pharma R&D is at a crossroads: the pressure to accelerate innovation, ensure compliance and manage fragmented data has never ...

Critical Path Institute® (C-Path) will host its 2026 Global Impact Conference (CGIC) this September at the Washington ...

In this week’s edition of InnovationRx, we look at a new AI drug development deal, a pill for sleep apnea, Commure’s $7 billion valuation, and more.

CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.

Big Pharma is pouring money into tech-devised treatments, but the verdict is out on whether they’ll actually work.

Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning.

Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a dual hub centered in the United States and China, according to new research ...